What the Spanish diagnostics market shows about competing through complex solutions

In complex healthcare markets, the best product is increasingly not enough. Customers are being asked to deliver more clinical value with constrained people and budgets, and the solutions they need now combine technology, workflow, service, supply, integration — and, often, capabilities that sit across several companies. When a customer is buying an outcome rather than a box, the question stops being whose product is best. It becomes who can assemble and stand behind the whole.

That changes what commercial leadership means, and Europe is where the change is sharpest — fragmented national and regional systems, public budgets under pressure, long-lived installed infrastructure, and an increasing appetite for integrated solutions. Spain shows the pattern clearly. More than half of the European IVD market is public and moves through tenders shaped by EU and national law; you might expect that to produce one common market, and it does not. Some countries still buy at the level of reagents and systems; Spain is among those buying large, integrated solutions, in consolidated decisions a hospital group will live with for years.

I know that market well — from years in the Iberia–LatAm organisation, from EMEA commercial roles where major deals were discussed and wins and losses examined, and, more recently, from being asked to bring the partnership element into Spanish projects directly.

A dependency that runs both ways

Start with something easy to overlook. Modern diagnostics is built on a deep mutual dependency between healthcare providers and industry. The provider depends on the industry for the innovation and the reliable supply without which a modern laboratory cannot run. The industry depends, just as much, on the providers — the customers it exists to serve.

That mutual dependency is the real subject. In a complex, integrated solution, the relationship between a laboratory and its principal supplier cannot be reduced to a transaction. A consolidated hospital group is committing to a diagnostic capability for years, and reaching a goal neither side reaches alone: investment on one side, long-term commitment on the other. It is choosing who will stand behind that capability through every renewal, every new clinical demand, every morning something breaks and has to be made right. A contract can define that partnership, but it cannot guarantee it. What decides the outcome is the partnership in spirit — and, when it is genuinely lived, that matters more than anything the contract sets down.

The pressure on both sides is the same across markets: financial and human-resource constraints on one hand, and on the other a demand that keeps rising, in volume and in sophistication. The industry has largely met that pressure by supporting substantial growth in laboratory output while growing more slowly itself, delivering major productivity gains to healthcare providers. That is the IVD promise kept: clinical value and productivity made compatible. And there is still room in it, if the way the industry and its customers work together can be improved.

What Spain shows

Spain regionalised its healthcare system long ago, creating distinct regional systems rather than one monolithic national service. Its major clinical laboratories are sophisticated customers: organised, demanding, clinically ambitious and accustomed to buying complex, integrated solutions.

That kind of customer does not choose on the product alone. Product excellence remains necessary. But in this kind of market, it is no longer sufficient. Increasingly, the differentiator is the team around it.

What the best teams actually do

That phrase is easy to say and easy to hollow out, so let me be specific about what a team like that is.

It is stable, because in a relationship measured in years the customer’s trust rests in particular people, and it resets every time those people change. It is local, because in diagnostics the service and supply that keep a laboratory running are delivered on the ground, and the customer knows exactly who looks after them. It is knowledgeable enough to hold the technical conversation where a real requirement is understood — clinical, operational, economic. And it can orchestrate partners, because the complete solution a hospital group needs often exceeds what any single supplier provides. When the customer’s need is larger than one company’s portfolio, the answer has to be assembled across companies and stood behind as one. Composing that whole — and taking responsibility for it — is the team’s work, not a product’s.

Behind all of that sits commercial leadership: someone deciding where to invest, which partnerships are worth assembling, which opportunities deserve resources, and when to stop pursuing one that will not come. Good teams need that judgment as much as they need technical and customer expertise.

There is also a threshold most people outside the market miss. Outside a formal tender, no customer owes a supplier its attention. Access is earned. Long before procurement begins, customers are learning — from incumbent performance, service experience, clinical evidence, new technologies and the alternatives challengers put in front of them. A strong team earns the credibility to be part of those conversations through serious, continuous work, not through a tender campaign.

Acting in time

The best team is also the one that reads a need early and moves while there is still a real choice to be made. I was asked to bring the partnership element into two Spanish projects, close together, where essentially the same commercial challenge resolved very differently.

In one, in a capital city, the customer’s view of the solution it wanted had already formed before a credible alternative could be understood and put together. Nothing was wrong with the answer. It simply arrived after the decision had taken shape, and a structural decision is expensive to reopen. There was little to be done that late.

In the other, in a remote city, the situation was still open. The unmet need — surfaced in part by what a challenger had put in front of the customer — was understood early. The right people were engaged, the new technology was evaluated on its merits, and the fuller solution was assembled around the customer’s real problem. The customer could then weigh a complete and well-understood set of options before moving into its formal procurement.

Same country, a similar commercial challenge, and two very different positions by the time the opportunity became concrete. What separated them was whether the team had anticipated the need and acted while there was still a genuine choice.

The work ahead

Many of the obvious productivity gains have already been captured. Laboratories are highly automated and increasingly digital, while the industry has supported far greater clinical output without equivalent market growth. The next gains are unlikely to come simply from more pressure on price. They will require better combinations of innovation, productivity, service and economically sustainable long-term solutions.

That makes the quality of the relationship between diagnostics companies and their customers more important, not less. And it makes the commercial team’s ability to understand, assemble and sustain the right solution increasingly consequential.

None of this is particular to Spain. Across Europe’s fragmented markets, the commercial challenge is no longer only to innovate. It is to turn innovation into economically sustainable solutions a customer can adopt and rely on — and that is won or lost on the ground, market by market, by the people closest to the customer.

When partnership is critical, the winner is not necessarily the company with the best product.

It is the one with the best team.